SERPINE1 mRNA binding protein 1 pseudogene 4Genealiases: []
Q-omics provides the consensus-scored SERBP1P4 profile across patient tissues and cancer cell-line models. SERBP1P4 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SERBP1P4 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, SERBP1P4 RNA expression shows 6,667 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, BRCA, and TGCT as cancer lineages where SERBP1P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SERBP1P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SERBP1P4 survival associations across molecular data types. SERBP1P4 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SERBP1P4 RNA expression–survival associations across cancer types. High SERBP1P4 expression shows unfavorable associations in KIRP, READ, KIRC, LUSC, UCEC and COAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SERBP1P4 RNA expression.
This table summarizes SERBP1P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SERBP1P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SERBP1P4 shows higher tumor expression in BRCA, LUSC and HNSC. The BRCA box plot shows higher SERBP1P4 RNA expression in tumor versus normal tissue (log2 FC = +0.009, t-test p = .007).
This table shows molecular features associated with SERBP1P4 in patient tissues and cancer cell lines. In patient samples, SERBP1P4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
